Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
Status: | Active, not recruiting |
---|---|
Conditions: | Prostate Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/23/2018 |
Start Date: | July 2015 |
End Date: | March 2020 |
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning: A Pilot Study to Quantitate the Potential to Limit Radiation Dose to Normal Tissues.
This research study is evaluating whether a standard prostate MRI examination can improve
radiation therapy planning for prostate cancer.
radiation therapy planning for prostate cancer.
In this research study, the investigators want to determine if prostate radiotherapy
treatment planning can be improved by using an MRI scan to help doctors more accurately
target the prostate with radiation and decrease radiation dose to the rectum, which is just
behind the prostate.
To do this, the investigators will create a treatment plan based on the MRI scan and compare
it to the standard treatment, which currently uses a CT scan rather than an MRI. The results
of this study will help inform doctors whether it is beneficial to routinely use an MRI scan
for prostate radiotherapy treatment planning.
treatment planning can be improved by using an MRI scan to help doctors more accurately
target the prostate with radiation and decrease radiation dose to the rectum, which is just
behind the prostate.
To do this, the investigators will create a treatment plan based on the MRI scan and compare
it to the standard treatment, which currently uses a CT scan rather than an MRI. The results
of this study will help inform doctors whether it is beneficial to routinely use an MRI scan
for prostate radiotherapy treatment planning.
Inclusion Criteria:
- Participants must have histologically confirmed prostate cancer.
- PSA level and prostate biopsy must be reviewed at Brigham and Women's Hospital or the
Dana Farber Cancer Institute and should support a diagnosis of stage I-III prostate
adenocarcinoma.
- Candidates with PSA greater than 20, digital rectal exam consistent with disease
outside the prostate (clinical T3/T4 disease), or Gleason score 8 or greater, should
have a bone scan and diagnostic pelvic CT or MRI to exclude metastatic disease.
- Prostate biopsy, serum PSA measurement, and any indicated diagnostic imaging studies
must be performed within 60 days of the date of registration.
- Participants should not have had prior curative local treatment for prostate cancer,
including no radiotherapy or prostatectomy. A maximum 90 days of systemic androgen
deprivation therapy prior to registration is allowed.
- Participation is limited to adult patients, age 18 years or older.
- ECOG performance status ≥2 (Karnofsky ≥60%)
- Life expectancy of greater than 10 years.
- Able to tolerate an MRI examination.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Participants with known or suspected metastatic (stage IV) prostate cancer.
- Participants with an implanted device, prosthesis, or any other foreign body with
ferromagnetic properties that would make them ineligible to undergo MRI examination.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.
We found this trial at
1
site
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Anthony V D'Amico, M.D. Ph.D.
Phone: 617-732-7936
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials